The rising prevalence of metabolic disorders, obesity, and lifestyle-related health conditions is increasing the demand for advanced NASH drugs, innovative MASLD treatment approaches, and next-generation hepatology therapeutics. Non-alcoholic steatohepatitis (NASH), now increasingly referred to as metabolic dysfunction-associated steatohepatitis (MASH), is a progressive...